Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Raymond James & Associates

Raymond James & Associates cut its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,515 shares of the company’s stock after selling 1,353 shares during the period. Raymond James & Associates’ holdings in Bausch Health Companies were worth $317,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Ausdal Financial Partners Inc. bought a new position in shares of Bausch Health Companies during the third quarter worth about $86,000. Jump Financial LLC bought a new position in shares of Bausch Health Companies during the third quarter worth about $92,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Bausch Health Companies during the third quarter worth about $103,000. Park Avenue Securities LLC bought a new position in shares of Bausch Health Companies during the third quarter worth about $169,000. Finally, Pathstone Family Office LLC bought a new position in shares of Bausch Health Companies during the third quarter worth about $169,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Price Performance

NYSE BHC opened at $8.71 on Monday. Bausch Health Companies Inc. has a 12 month low of $5.57 and a 12 month high of $11.46. The firm has a market capitalization of $3.18 billion, a PE ratio of -5.38 and a beta of 0.85. The company’s 50 day simple moving average is $9.30 and its 200 day simple moving average is $8.18.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The business had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the business earned $1.02 earnings per share. Sell-side analysts anticipate that Bausch Health Companies Inc. will post 3.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BHC has been the topic of a number of recent research reports. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Jefferies Financial Group cut their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Finally, Royal Bank of Canada cut their price target on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 23rd.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.